Minister of State Mansukh Mandaviya today assured that the Government is monitoring the supply of each COVID-19 Essential Drug. All drugs used in the management of COVID-19 are now available in India by ramping up production and increasing imports.

The availability of these drugs is being monitored by implementing the three-pronged strategy of Supply Chain Management, Demand Side Management and Affordability.

Protocol Drugs:

  1. Remdesivir
  2. Enoxaparin
  3. MethylPrednisolone
  4. Dexamethasone
  5. Tocilizumab
  6. Ivermectin

Non-protocol Drugs:

  1. Favipiravir
  2. Amphotericin
  3. Apixaban

CDSCO and NPPA are coordinating with manufacturers to enhance production and getting data about current stock, current capacities, Projected production for May 2021.


Number of plants producing Remdesivir increased from 20 to 60 resulting in 3 times more availability in just 25 days.

Production ramped up 10 times, from 10 lakhs vials/month in April’21 to ~1 crore/ month in May’21.

Toscilizumab injection:

It is made available in the country by importing 20 times more than what was being done in normal times.

Dexamethasone 0.5 mg tablets:

Production enhanced from 6-8 times within a month

Dexamethasone Injection production ramped up almost 2 times.

Enoxaparin Injection production increased 4 times in a mere one month.

Methyl Prednisolone Injection:

Production increased almost 3 times in a month’s time.

Ivermectin 12 mg tab production enhanced in the country by ~5 times within a month from 150 lakhs in April to 770 lakhs in May,2021.


A non-protocol drug but it is used to lower the virus load.

The production increased 4 times within a month

From 326.5 lakh in April,21 to 1644 lakh in May,21.

Amphoterecin B Injection:

Production ramped up ~ 3 times in a month.

80 lakh vials are in production and

3 lakh vials are being imported

Total 6.80 lakh vials will be available in the country.